Robatumumab
CD221 | |
|---|---|
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6418H9960N1732O1992S42 |
| Molar mass | 144602.93 g·mol−1 |
  (what is this?) (verify) | |
Robatumumab (proposed
CD221, the insulin-like growth factor 1 receptor.[1]
Phase 2 clinical trials in patients with colorectal cancer, osteosarcoma and Ewing's sarcoma are complete.[2][3] Merck has since discontinued development.[4]
References
- ^ "robatumumab", p. 337 in: Quality Assurance and Safety of Medicines (2008). Encrenaz C (ed.). "Proposed International Nonproprietary Names: List 100" (PDF). WHO Drug Information. 22 (4): 311–67.
- PMID 27362300.
- ^ Clinical trial number NCT00551213 for "A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)" at ClinicalTrials.gov
- ^ "Robatumumab". Adis Insight. Springer Nature Switzerland AG.